These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 28554266

  • 21. Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients.
    Ding L, Zhang FB, Liu H, Gao X, Bi HC, Huang L, Wang XD, Chen BL, Zhang Y, Lv C, Hu PJ, Huang M.
    Pharmacol Res Perspect; 2021 May; 9(3):e00764. PubMed ID: 33929082
    [Abstract] [Full Text] [Related]

  • 22. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
    Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ.
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
    [Abstract] [Full Text] [Related]

  • 23. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
    López-Martín C, Chaparro M, Espinosa L, Bejerano A, Maté J, Gisbert JP.
    Gastroenterol Hepatol; 2011 Jan; 34(6):385-92. PubMed ID: 21616565
    [Abstract] [Full Text] [Related]

  • 24. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
    Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA.
    Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
    [Abstract] [Full Text] [Related]

  • 25. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
    Seinen ML, van Nieuw Amerongen GP, de Boer NK, Mulder CJ, van Bezu J, van Bodegraven AA.
    Ther Drug Monit; 2016 Oct; 38(5):621-7. PubMed ID: 27465973
    [Abstract] [Full Text] [Related]

  • 26. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB, Peyrin-Biroulet L, Sparrow MP.
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
    Amin J, Huang B, Yoon J, Shih DQ.
    Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
    [Abstract] [Full Text] [Related]

  • 29. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
    Makuuchi M, Kakuta Y, Umeno J, Fujii T, Takagawa T, Ibuka T, Miura M, Sasaki Y, Takahashi S, Nakase H, Kiyohara H, Tominaga K, Shimodaira Y, Hiraoka S, Ueno N, Yanai S, Yoshihara T, Kakimoto K, Matsuoka K, Hayashi R, Nanjo S, Iwama I, Ishiguro Y, Chiba H, Endo K, Kagaya T, Fukuda T, Sakata Y, Kudo T, Takagi T, Takahashi K, Naganuma M, Shinozaki M, Ogata N, Tanaka H, Narimatsu K, Miyazaki H, Ishige T, Onodera M, Hashimoto Y, Nagai H, Shimoyama Y, Naito T, Moroi R, Shiga H, Post-MENDEL study group, Kinouchi Y, Andoh A, Hisamatsu T, Masamune A.
    J Gastroenterol; 2024 Jun; 59(6):468-482. PubMed ID: 38589597
    [Abstract] [Full Text] [Related]

  • 30. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
    Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, Nishida A, Nakagawa S, Miura M, Toyonaga T, Onodera K, Shinozaki M, Ishiguro Y, Mizuno S, Takahara M, Yanai S, Hokari R, Nakagawa T, Araki H, Motoya S, Naito T, Moroi R, Shiga H, Endo K, Kobayashi T, Naganuma M, Hiraoka S, Matsumoto T, Nakamura S, Nakase H, Hisamatsu T, Sasaki M, Hanai H, Andoh A, Nagasaki M, Kinouchi Y, Shimosegawa T, Masamune A, Suzuki Y, MENDEL study group.
    J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
    [Abstract] [Full Text] [Related]

  • 31. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
    Broekman MMTJ, Coenen MJH, van Marrewijk CJ, Wanten GJA, Wong DR, Verbeek ALM, Klungel OH, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, de Jong DJ, TOPIC Recruitment Team.
    Inflamm Bowel Dis; 2017 Oct; 23(10):1873-1881. PubMed ID: 28644183
    [Abstract] [Full Text] [Related]

  • 32. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine.
    Bowen DG, Selby WS.
    Dig Dis Sci; 2000 Sep; 45(9):1810-3. PubMed ID: 11052324
    [Abstract] [Full Text] [Related]

  • 33. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
    Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):654-61. PubMed ID: 19183142
    [Abstract] [Full Text] [Related]

  • 34. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, De Teresa-Galván J, Redondo-Cerezo E.
    World J Gastroenterol; 2013 Aug 14; 19(30):4877-86. PubMed ID: 23946592
    [Abstract] [Full Text] [Related]

  • 35. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine.
    Barnes BH, Borowitz SM, Saulsbury FT, Hellems M, Sutphen JL.
    J Pediatr Gastroenterol Nutr; 2004 May 14; 38(5):509-12. PubMed ID: 15097439
    [Abstract] [Full Text] [Related]

  • 36. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
    Gensmyr-Singer H, Werner M, Karling P.
    Therap Adv Gastroenterol; 2024 May 14; 17():17562848241228064. PubMed ID: 38384282
    [Abstract] [Full Text] [Related]

  • 37. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients.
    de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den Hartog G, Hooymans PM, Mäkelburg AB, Westerveld BD, Naber AH, Mulder CJ, de Jong DJ.
    World J Gastroenterol; 2005 Sep 21; 11(35):5540-4. PubMed ID: 16222751
    [Abstract] [Full Text] [Related]

  • 38. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK.
    Ther Drug Monit; 2015 Dec 21; 37(6):797-804. PubMed ID: 25853923
    [Abstract] [Full Text] [Related]

  • 39. What are the rules when treatment with 6-MP/AZA is started?
    Korelitz BI.
    Inflamm Bowel Dis; 2008 Oct 21; 14 Suppl 2():S262-3. PubMed ID: 18816727
    [No Abstract] [Full Text] [Related]

  • 40. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
    Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Syriopoulou VP, Goutas N, Vlachodimitropoulos D, Anagnou NP, Roma-Giannikou E.
    J Clin Pharm Ther; 2010 Feb 21; 35(1):93-7. PubMed ID: 20175817
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.